Navigation Links
Regeneron Provides Update On FDA Advisory Committee Discussion of ARCALYST® (rilonacept) Injection
Date:5/8/2012

nacept.  It is recommended that patients receive all recommended vaccinations prior to initiation of treatment with rilonacept.  Patients should be monitored for changes in their lipid profiles and provided with medical treatment if warranted.  Hypersensitivity reactions associated with rilonacept administration have been rare.  Please see the full Prescribing Information for ARCALYST® (rilonacept), available online at www.regeneron.com/ARCALYST-fpi.pdf.

About Regeneron Pharmaceuticals
Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets two products in the United States, ARCALYST® (rilonacept) Injection for Subcutaneous Use and EYLEA® (aflibercept) Injection, and has filed regulatory applications with the U.S. Food and Drug Administration (FDA) for second indications for each of these products.  A regulatory application has also been submitted to the FDA for the product candidate ZALTRAP® (aflibercept) Concentrate for Intravenous Infusion.  Phase 3 studies are in progress with EYLEA® in a third indication, and with product candidate sarilumab.  Earlier-stage clinical programs are underway with nine additional monoclonal antibodies.  Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia.  Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.

Regeneron Forward-Looking Statements
This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regenero
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Regeneron and Bayer Announce Co-Promotion Agreement With Santen For EYLEA® (aflibercept) Injection in Japan
2. Regeneron to Report First Quarter 2012 Financial and Operating Results and Host Conference Call and Webcast on April 26, 2012
3. Regeneron Announces Data Publication and Presentations with Potential First-in-Class Lipid-Lowering PCSK9 Antibody
4. Regeneron Announces February 2012 Investor Conference Presentations
5. Regeneron to Report Full Year 2011 Financial and Operating Results and Host Conference Call and Webcast on February 16, 2012
6. Regeneron Announces Settlement of Patent Litigation with Genentech for U.S. Ophthalmic Sales of EYLEA™ (aflibercept) Injection
7. Regeneron to Host Conference Call on January 3 at 8:30 a.m. Eastern Time to Discuss Ongoing Patent Litigation
8. Regeneron Announces Presentation Time Change at the 2011 Deutsche Bank BioFEST
9. Regeneron Announces FDA Acceptance of ARCALYST® (rilonacept) Supplemental Biologics License Application for Review
10. Rockefeller University President Marc Tessier-Lavigne Elected to Regeneron Board of Directors
11. Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... Dec. 23, 2014   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... of the Marketing Authorization Application (MAA) for sebelipase ... the company,s request for accelerated assessment, which has ... time.   The MAA, and the ...
(Date:12/24/2014)... Dec. 23, 2014 Tianyin Pharmaceutical Co., ... specializes in patented biopharmaceutical, modernized traditional Chinese medicine ... today announced that the Company achieved the Public ... Practice (GMP) certificate of TPI,s Qionglai Facility (QLF) ... The public notice period is a significant procedure ...
(Date:12/22/2014)... 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical ... purification technology to help fight deadly inflammation in ... worldwide, today announced the appointment of Dr. ... its Senior Vice President of Clinical Development, effective ... Di Russo is an accomplished pediatric cardiothoracic ...
Breaking Medicine Technology:Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... PHILADELPHIA, Pa. June 20 GlaxoSmithKline,(NYSE: GSK ... and Drug,Administration has extended the priority review period ... treated patients,with chronic idiopathic thrombocytopenic purpura, as they ... Drug User Fee action date has,been extended to ...
... OAK LAWN, Ill., June 20 Advocate Christ,Medical Center ... a few institutions,in the Chicago area, the only one ... hospitals nationally that are using a glue-like liquid for,the ... a recent two-and-a-half-hour procedure, Thomas J. Grobelny MD, of,the ...
Cached Medicine Technology:GSK Update on FDA Review of Promacta(R) (Eltrombopag) 2Advocate Christ Medical Center Using Glue-Like Liquid to Seal Off Brain Aneurysms 2
(Date:12/25/2014)... (PRWEB) December 26, 2014 ... BambooFlooringChina.com combines beauty, strength and durability. Today, the ... promotion, which is valid until Jan. 30, 2015. ... grain of traditional hardwood. BambooFlooringChina.com is a well-known ... help consumers worldwide to find a reliable bamboo ...
(Date:12/25/2014)... 2014 The report “TS-1 (Colorectal Cancer) ... the current treatment landscape, unmet needs, current pipeline and ... an anti-cancer drug which is typically used for treating ... used for treating gastric cancer and pancreatic cancer. TS-1 ... drug was first approved in 1999 in Japan for ...
(Date:12/25/2014)... 26, 2014 “Every three months the trends ... A-line sweetheart evening dress will be one of the hottest ... of Yunx.co.uk says. Today, the company releases 26 A-line sweetheart ... to 80% off. , “We are trying our best ... with our latest designs. Along with affordable prices, we provide ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying women’s ... discounted prom dresses, most of which are priced under ... company, the promotion is valid until Jan. 22, 2015; ... UK market. , The prom dresses in this new ... A-line strapless, empire strapless chiffon, one shoulder, floor-length, V-neck ...
(Date:12/25/2014)... 2014 Recently, BellasDress has ... its wedding dresses. BellasDress has chosen their best-selling lace ... choices for the holiday season. , Now, BellasDress.com ... wedding gowns here at discount prices. The business hopes ... its website. , “All our elegant products ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2
... has been identified as the "signature injury" of the ... is known to cause deficits in memory, attention and ... disorder (PTSD), depression, anxiety disorders and substance abuse. , ... TBI, based on statistics gathered by the Veterans Administration,s ...
... woman receives vitamins to prevent birth defects of the brain ... link between periodontal disease and preterm and low birth weight ... oral health. Asian- and Spanish-speaking women learn the signs of ... being helped through local grants announced today by the March ...
... Recession there is at least one company making sure ... boardrooms around the nation, business leaders are sitting down ... recession on their business. Layoffs, cutbacks and downsizing ... Aegis Living (http// www.AegisLiving.com ) a national leader in ...
... can indicate whether vaginal birth would be safe, study says ... of the uterine scar from a cesarean delivery can help ... uterine rupture and may safely try to have a vaginal ... "The thicker the scar is, the stronger the scar is, ...
... Smithfield Foods, Inc. (NYSE: SFD ) announced ... with The National Breast Cancer Foundation in effort to ... Smithfield,s Lean Generation(R) Deli ( www.leangenerationdeli.com ) contributed more ... The National Breast Cancer Foundation is an extremely effective ...
... California at San Diego have come up with a ... of nanotubes and stem cells. This new finding could ... patients who undergo orthopedic surgery., In recent years, stem ... studies suggesting revolutionary medical benefits due to their ability ...
Cached Medicine News:Health News:Study of Iraq veterans' traumatic brain injuries to be conducted by UB researchers 2Health News:Seven Washington Organizations Receive Almost $126,000 Through March of Dimes Awards and Grants 2Health News:Seven Washington Organizations Receive Almost $126,000 Through March of Dimes Awards and Grants 3Health News:Seven Washington Organizations Receive Almost $126,000 Through March of Dimes Awards and Grants 4Health News:Aegis Living Focuses On Taking Care of Their Own in 2009 2Health News:Aegis Living Focuses On Taking Care of Their Own in 2009 3Health News:Using C-Section Scars to Predict Future Deliveries 2Health News:Using C-Section Scars to Predict Future Deliveries 3Health News:Smithfield Foods' Lean Generation(R) Deli Partnership with National Breast Cancer Foundation Celebrates $135,000 Contribution 2Health News:UC San Diego engineers develop novel method for accelerated bone growth 2Health News:UC San Diego engineers develop novel method for accelerated bone growth 3
... Complete procedure information to facilitate diagnostic ... monitor is a sterile, disposable device used ... nucleus during discography procedures. The device will ... display it in a digital format. The ...
Smith & Nephew's CDS System is developed exclusively for discography., Developed exclusively for discography, it is the first system designed to measure true disc pressure and record real-time proce...
The ACCU-DISC™ pressure monitoring system offers the advantage of accurate delivery of fluids to the body with the ability to monitor the pressure of those fluids in discography interpretation....
The °CureWrap is one-piece garment offers maximum available surface coverage, while avoiding the sterilized fields of operation....
Medicine Products: